5,7-二氟-3,4-二氢-2H-萘-1-酮 | 110931-79-8

• 物质功能分类: 化学试剂 - 有机试剂 - 多环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 5,7-二氟-3,4-二氢-2H-萘-1-酮
• 英文名称: 5,7-difluoro-3,4-dihydronaphthalen-1(2H)-one
• 英文别名: 5,7-difluoro-1,2,3,4-tetrahydronaphthalen-1-one；5,7-difluoro-3,4-dihydro-2H-naphthalen-1-one
• CAS: 110931-79-8
• 化学式: C₁₀H₈F₂O
• 分子量: 182.17
• InChiKey: WNXVYUPXXGLTSF-UHFFFAOYSA-N

物化性质

• 沸点：
  260.7±40.0 °C(Predicted)
• 密度：
  1.290±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温和干燥环境

反应信息

• 作为反应物：
  描述：

  5,7-二氟-3,4-二氢-2H-萘-1-酮 在 sodium tetrahydroborate 、 lithium aluminium tetrahydride 、 对甲苯磺酸 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 甲醇 、 氯仿 、 苯 为溶剂， 生成 5,7-difluorotetralol
  参考文献：
  名称：

  Kinetic enzymatic resolution of β-tetralols

  摘要：

  Several substituted beta-tetralols 1a-e and beta-tetralol 2 were successfully resolved using porcine pancreatin in hydrocarbon solvents. All attempts to resolve the substituted beta-tetralols by diasteromeric derivatization have failed. The absolute configuration of the products was established by literature precedence.

  DOI：

  10.1016/0957-4166(95)00180-w
• 作为产物：
  描述：

  1,3-二氟苯 在 palladium on activated charcoal 盐酸 、 sodium hydroxide 、 三氯化铝 、 氯化亚砜 、 amalgamated zinc 、 氢气 、 溶剂黄146 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 52.5h， 生成 5,7-二氟-3,4-二氢-2H-萘-1-酮
  参考文献：
  名称：

  Synthesis and structure-activity relationships of naphthalene-substituted derivatives of the allylamine antimycotic terbinafine

  摘要：

  Derivatives of the allylamine antimycotic terbinafine (1) with varied substitution at the naphthalene ring system have been prepared, and their antifungal activity has been evaluated. In general, the potency is strongly dependent on the bulkiness of the substituent. Only hydrogen or in some cases fluorine are tolerated as substituents at positions 2-4 and 6-8 of the naphthalene moiety, whereas 5-substituents may be larger in size (F, Cl, Br, Me). Derivatives with fluorine at positions 3, 5, and 7 or chlorine at position 5 showed enhanced activity against yeasts relative to 1. This increase in sensitivity could be intensified by simultaneous introduction of two fluoro substituents at positions 5 and 7. Compound 7q demonstrated 8-to 16-fold improved potency against Aspergillus fumigatus, Candida albicans, and Candida parapsilosis.

  DOI：

  10.1021/jm00071a011

文献信息

• PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
  申请人：Incyte Corporation

  公开号：US20180072720A1

  公开（公告）日：2018-03-15

  Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

  揭示了化合物的公式（I），使用这些化合物抑制HPK1活性的方法以及包含这些化合物的药物组合物。这些化合物在治疗、预防或改善与HPK1活性相关的疾病或紊乱方面是有用的，如癌症。
• Amine derivatives, processes for their production and their use
  申请人：Sandoz, Ltd.

  公开号：US04939148A1

  公开（公告）日：1990-07-03

  Compounds of formula I ##STR1## wherein R.sub.1 represents a group of formula ##STR2## and R.sub.2 represents hydrogen or lower alkyl, or R.sub.1 and R.sub.2 together with the carbon atom to which they are attached represent a group of formula IIg ##STR3## R.sub.4 and R.sub.5 represent independently hydrogen or lower alkyl, R.sub.3 represents hydrogen, alkyl, cycloalkyl or halogenalkyl and R.sub.6 represents a group of formula ##STR4## R.sub.1 represents a group of formula IIa to IIf as defined above, R.sub.2 and R.sub.3 together form a --(CH.sub.2)--.sub.u group wherein u stands for a whole number from 1 to 8 and R.sub.4, R.sub.5 and R.sub.6 have the meanings given above. which compounds are indicated for use as pharmaceuticals and agrochemicals.

  化合物的化学式I ##STR1## 中，其中R.sub.1代表化学式##STR2## 的基团，R.sub.2代表氢或较低的烷基，或者R.sub.1和R.sub.2与它们连接的碳原子一起代表化学式IIg ##STR3## 的基团，R.sub.4和R.sub.5独立地代表氢或较低的烷基，R.sub.3代表氢、烷基、环烷基或卤代烷基，R.sub.6代表化学式##STR4## 的基团，R.sub.1代表如上定义的化学式IIa到IIf的基团，R.sub.2和R.sub.3一起形成一个--(CH.sub.2)--.sub.u基团，其中u代表从1到8的整数，R.sub.4、R.sub.5和R.sub.6具有上述给定的含义。这些化合物被指示用作药物和农药。
• PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
  申请人：Incyte Corporation

  公开号：US20180072741A1

  公开（公告）日：2018-03-15

  Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

  揭示了化合物的结构式（I），使用这些化合物抑制HPK1活性的方法以及包含这些化合物的药物组合物。这些化合物可用于治疗、预防或缓解与HPK1活性相关的疾病或疾病，如癌症。
• Benzocycloalkylazolethione derivatives
  申请人：——

  公开号：US05538988A1

  公开（公告）日：1996-07-23

  The present invention relates to novel benzocycloalkylazolethione compounds which are dopamine .beta.-hydroxylase inhibitors in which the benzocycloalkyl portion of the compound is selected from indanyl, 1,2,3,4-tetrahydronaphthalenyl and 6,7,8,9-tetrahydro-5H-benzocycloheptenyl (in which the benzo is optionally substituted with one to three substituents) and the azolethione portion of the compound is selected from 2-thioxo-2,3-dihydro-1H-imidazol-3-yl, 5-thioxo-4,5-dihydro-1H-[1,2,4]triazol-4-yl and 5-thioxo-4,5-dihydro-1H-[1,2,4]triazol-1-yl (each optionally substituted with one to three substituents); and the prodrugs, pharmaceutically acceptable salts, individual isomers and mixtures of isomers and the methods of using and preparing such benzocycloalkylazolethione compounds.

  本发明涉及一种新型苯并环烷基唑硫酮化合物，它们是多巴胺β-羟化酶抑制剂，其中化合物的苯并环烷基部分选自吲哚基、1,2,3,4-四氢萘基和6,7,8,9-四氢-5H-苯并环庚基（其中苯并基可选择性地取代一个到三个取代基），化合物的唑硫酮部分选自2-硫代-2,3-二氢-1H-咪唑-3-基、5-硫代-4,5-二氢-1H-[1,2,4]三唑-4-基和5-硫代-4,5-二氢-1H-[1,2,4]三唑-1-基（每个可选择性地取代一个到三个取代基）；以及这些苯并环烷基唑硫酮化合物的前药、药学上可接受的盐、各个异构体和异构体混合物的使用和制备方法。
• 1-\x9b.omega.-(3,4-dihydro-2-naphthalenyl)alkyl!-cyclic amine derivatives,
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：US05847159A1

  公开（公告）日：1998-12-08

  1-\x9b.omega.-(3,4-Dihydro-2-naphthalenyl)alkyl!cyclic amine derivative of the formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are H, halogen, OH, alkyl, alkoxy, hydroxymethyl, etc., or R.sup.1 and R.sup.2 combine to form methylenedioxy, trimethylene, etc., R.sup.3 is H, etc., R.sup.4 is H, OH, alkyl, etc., R.sup.5 is H, alkyl, etc., p is integer of from 2 to 6, and q is integer of from 3 to 7, provided that when p is 2, and q is 5, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are not simultaneously H, or salts thereof, or N-oxide derivatives thereof, or a process for preparing the same, or pharmaceutical composition containing the same. The compounds of the present invention show potent inhibitory effect on the micturition reflex, and are useful as agents for treatment of frequent urination and urinary incontinence.

  化合物的式(I)为：1-\x9b.omega.-(3,4-二氢-2-萘基)烷基!环状胺衍生物，其中R.sup.1和R.sup.2为H、卤素、OH、烷基、烷氧基、羟甲基等，或R.sup.1和R.sup.2结合形成亚甲二氧基、三亚甲基等，R.sup.3为H等，R.sup.4为H、OH、烷基等，R.sup.5为H、烷基等，p为2到6的整数，q为3到7的整数，但当p为2，q为5时，R.sup.1、R.sup.2、R.sup.3、R.sup.4和R.sup.5不能同时为H，或其盐，或其N-氧化物衍生物，或制备它们的方法，或包含它们的制药组合物。本发明化合物表现出强效的抑制排尿反射的作用，可用作治疗频繁排尿和尿失禁的药物。